At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 207 enrolled
Drug / intervention
Teriparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis
In Brief
A Phase 3 clinical trial evaluating Teriparatide and Placebo for Osteoporosis. Completed, enrolled 207 participants across 16 sites.
Detailed Summary
To evaluate the efficacy of teriparatide based on measurements of bone mineral density at lumbar spine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedFeb 2007
Primary CompletionSep 2008
Study CompletionSep 2009
TodayJul 2026
First PostedFeb 9, 2007
Enrollment StartJan 1, 2007
Primary CompletionSep 1, 2008
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.4 years ago
Interventions
Teriparatidedrug
daily, subcutaneous
Placebodrug
daily, subcutaneous